NEW YORK, Feb. 1 (GenomeWeb News) - Qiagen and Protedyne will jointly market the use of Protedyne's BioCube system with Qiagen's QIAamp nucleic acid purification products for use in high-throughput research and molecular diagnostics, the companies said today.
In addition, Qiagen will invest approximately $2 million in Protedyne's current Series D financing round, the companies said.
Qiagen has exclusive access to BioCube, Protedyne's high-throughput automation platform. The companies originally agreed to develop the high-throughput nucleic acid sample-preparation platform in June 2004.
The companies said that the first commercial platform will be available in the second quarter of 2005, at which point both parties are expected to expand their collaboration by adding and validating additional applications.